西罗莫司片是哪个国家的？

(Lei Pa Ming) Which country is it from? Sirolimus tablets (rapamin) were originally manufactured by Wyeth Pharmaceuticals Company and later by Pfizer in the United States.

Sirolimus tablets (rapamin) inhibit the activation and proliferation of T lymphocytes stimulated by antigens and cytokines (interleukins IL-2, IL-4 and IL-15). It also inhibits the production of antibodies. In cells, sirolimus (rapamin) binds to the immunophilin, FK-binding protein-12 (FKBP-12), to generate the FKBP-12 immunosuppressive complex. This complex binds to mammalian sirolimus tablets (rapamin) BA molecule (mTOR, a key regulatory kinase) and inhibits its activity, thereby inhibiting the progression from G1 phase to S phase in the cell cycle.

Trial 1 was conducted at 38 research sites in the United States, with 719 patients participating. Randomly assigned after transplantation: 284 patients received sirolimus tablets (rapamin) 2 mg/day, 274 patients received sirolimus tablets (rapamin) 5 mg/day, and 161 patients received azathioprine 2-3 mg/kg/day. Trial 2 was conducted at 34 research units in Australia, Canada, Europe and the United States, with 576 patients participating. Randomly assigned before transplantation: 227 patients received sirolimus tablets (rapamin) 2 mg/day, 219 patients received sirolimus tablets (rapamin) 5 mg/day, and 130 patients received placebo. In both trials, antilymphocyte antibody induction therapy was contraindicated. In both trials, the primary efficacy endpoint was the rate of treatment failure within the first 6 months after transplantation. Treatment failure was defined as the first episode of acute rejection (confirmed by biopsy), graft loss, or death. Trial analysis results: Compared with azathioprine and placebo, sirolimus tablets (rapamin) at 2 mg/day and 5 mg/day dosage levels significantly reduced the incidence of treatment failure 6 months after transplantation.

The above is the manufacturer of (Leipaming) provided by our Medical Companion Brigade, as well as its effects.

Recommended related hot articles: /newsDetail/76750.html